Yi Tang

Yi Tang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
YTYi Tang
Yi Tang
ZTZhenyong Tang
Zhenyong Tang
JYJianrong Yang
Jianrong Yang
TLTianqi Liu
Tianqi Liu
YTYuntian Tang
Yuntian Tang
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor derived from intrahepatic bile duct epithelial cells. Accumulating studies report that microRNAs are widely involved in tumor migration and metastasis by regulation of target genes. miR-7-5p has been confirmed to inhibit tumor metastasis and to be related to prognosis for several malignant tumors. Our study investigated the underlying functions of miR-7-5p in ICC.

24 January 2023 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
SZShao-Liang Zhu
Shao-Liang Zhu
ZTZhenyong Tang
Zhenyong Tang
MZMengjie Zou
Mengjie Zou
TTTingting Tan
Tingting Tan
YTYi Tang
Yi Tang
JYJianrong Yang
Jianrong Yang
Background. Emerging evidence has shown that two common genetic polymorphisms within the pleckstrin domain-containing protein 5 (DEPDC5), rs1012068 and rs5998152, may be associated with the risk of hepatocellular carcinoma (HCC), especially in those individuals chronically infected with the hepatitis C virus (HCV) or the hepatitis B virus (HBV). However, these findings have not been consistently replicated in the literature due to limited sample sizes or different etiologies of HCC. Thus, the present systematic review and meta-analysis were performed to resolve this inconsistency. Methods. The databases PubMed, Embase, Web of Science, the China National Knowledge Infrastructure, and Scopus were searched up to December 12, 2022. Data from relevant studies were pooled, and odds ratios and 95% confidence intervals were calculated. Results. A total of 11 case-control studies encompassing 2,609 cases and 8,171 controls on rs1012068 and three encompassing 411 cases and 1,448 controls on rs5998152 were included. Results indicated that the DEPDC5 rs1012068 polymorphism did not significantly increase HCC risk in the total population (allelic model (OR = 1.32, 95% CI = 1.04–1.67, = 0.02); the recessive model (OR = 1.42, 95% CI = 0.96–2.10, = 0.08); the dominant model (OR = 1.43, 95% CI = 1.09–1.87, = 0.01); the homozygous model (OR = 1.61, 95% CI = 1.01–2.57, = 0.05); the heterozygous model (OR = 1.39, 95% CI = 1.09–1.79, = 0.009)). Subgroup analyses based on ethnicity and etiology revealed that the rs1012068 polymorphism, under all five genetic models, was associated with increased HCC risk in Asians or in individuals with chronic HBV infection but not in individuals with chronic HCV infection. A significant association was also observed between rs5998152 and HCV-related HCC risk in Asians chronically infected with HCV under allelic, dominant, and heterozygous models. Conclusion. Our study suggests that the DEPDC5 rs1012068 polymorphism increases HCC risk, especially in Asians with chronic HBV infection, while the rs5998152 polymorphism increases HCC risk in Asians with chronic HCV infection.